Physiomics Regulatory News (PYC)

12 February 2026

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded New Contract

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new biopharmaceutical client headquartered in South Korea.

This new project is with a South Korean clinical stage biopharmaceutical company focused on the development of next-generation antibody drug conjugate (ADC) and Immuno-oncology therapeutic for the treatment of cancer. Under the terms of the contract, Physiomics will use PK/PD modelling and simulation techniques to support dosing decisions for one of the client's clinical stage assets. The project, valued at up to £66,600, will commence immediately with completion anticipated within the next two months.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been selected to partner with this new South Korean client on their important clinical stage programme. This engagement underscores Physiomics' continued commitment to deliver robust quantitative insights that de-risk development strategies and enhance decision making, whilst reflecting the Company's efforts to reach new clients in markets further afield. We look forward to applying our expertise to support this client in achieving their development goals."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.